Quality of life following allogeneic stem cell transplantation for patients age >60 years with acute myelogenous leukemia

Wright, Rachel, Oremek, Maximilian, Davies, David, Kewley, Caitlin, Singh, Alyssa, Taitt, Nathaniel, Kempshall, Emma, Wilson, Keith and Ingram, Wendy 2020. Quality of life following allogeneic stem cell transplantation for patients age >60 years with acute myelogenous leukemia. Biology of Blood and Marrow Transplantation 26 (8) , pp. 1527-1533. 10.1016/j.bbmt.2020.04.020

Full text not available from this repository.

Abstract

This study of patients with acute myelogenous leukemia (AML) age60 years analyzed the association betweenpatients’performance indices—Hematopoietic Stem Cell Transplantation Comorbidity Index (HCT-CI), KarnofskyPerformance Score (KPS), and European Society for Blood and Marrow Transplantation (EBMT) risk score—beforeundergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and quality of life (QoL), quantifiedusing the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), in thefirst yearafter allo-HSCT. Over a period of 7 years, 48 evaluable patients underwent reduced-intensity conditioning allo-HSCT. The median patient age was 65 years (range, 60 to 74 years), with 2-year and 5-year overall survival (OS) of65.8% and 52.3%, respectively. A significant improvement across all QoL scores was observed over the 12 monthspost-HSCT. An HCT-CI of 0 was associated with improved general QoL (FACT-G) score at 6 months compared withpatients with an HCT-CI of 1 to 2 (P= .032). At 12 months post-HSCT, a pretransplantation HCT-CI3 was corre-lated with lower QoL scores across the domains (symptom-related QoL [FACT-TOI],P= .036; FACT-G,P= .05; BMT-related QoL [FACT-BMT],P= .036). A pretransplantation KPS score of 100 versus 80 to 90 was predictive ofimproved QoL at 6 months post-HSCT (FACT-TOI,P= .009; FACT-G,P= .001; FACT-BMT,P= .002) but not at 1 yearpost-HSCT. We demonstrate that KPS and HCT-CI can predict QoL in the early post-transplantation period, with afavorable overall survival in a selected cohort of AML patients age60 years.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	1083-8791
Date of Acceptance:	16 April 2020
Last Modified:	06 May 2023 02:11
URI:	https://orca.cardiff.ac.uk/id/eprint/132924

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item